This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

CANVAS Program - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Authoring team

CANVAS Program - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk

  • participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks
  • primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke
  • the CANVAS Program was a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials (1,2)

Results:

The study authors concluded:

  • "...in two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal..."

Key findings:

  • CANVAS Program met its primary objective of demonstrating the cardiovascular safety and efficacy of canagliflozin
  • canagliflozin use was associated with an increased risk of amputation which should be taken into consideration when prescribing this agent
  • data suggest a favorable benefit/risk profile with canagliflozin treatment in many patients with type 2 diabetes and high cardiovascular risk

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.